Project without external funding

Verankerte cAMP-Signale - Implikation in die Behandlung menschlicher Erkrankungen

Project Details
Project duration: 11/200210/2005

The specific scientific aim of the proposal is to understand complex and integrated intracellular signalling networks involving the signal compound cAMP and how such networks require anchoring and localization in the cell. This knowledge is crucial for evaluation of the clinical importance of cAMP signalling and for developing new therapeutic strategies towards diseases where cAMP signalling is implicated.
Cellular signalling is inherent to multicellular life. It allows the multitude of processes in individual cells to proceed in a coordinated fashion to the benefit of the organism. In the human body, logistic signals travel between cells in the nervous system, via the blood stream and locally inside tissues. At the cell border (membrane), signals are transduced and travel further into the cell interior, where they become integrated with other signals and finally target specific processes controlling cell division, specialisation (differentiation), energy consumption (metabolism), gene transcription, and many other cellular functions.
Signalling networks involving the signal molecule cAMP are involved in regulation of a myriad of body functions involving most organ systems of the body. The list of vital functions is long and encompasses some of the major health problems in the European Community including, but by no means restricted to, cancer, cardiovascular disease, type II diabetes, obesity, HIV infection and AIDS, asthma and chronic obstructive pulmonary disease, and various genetic diseases such as diabetes insipidus and muscular dystrophies - all major chronic diseases that subsume an enormous amount of the monetary and human resources of the European medical community. However, no systematic approach has explored the therapeutic potential in targeting the cAMP signal pathway in conditions such as listed above with a dysregulated cAMP signal pathway. Furthermore, although receptor agonists and antagonists (e.g. 1-adrenergic blocker, 2-agonist,) are established and an inhibitor of PDE3 is in use, no drugs have been marketed that specifically target the cAMP signal pathway.

Last updated on 2017-11-07 at 14:16